The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.
 
Karan Chohan
No Relationships to Disclose
 
Lorenzo Gensini
No Relationships to Disclose
 
Sherif Seif
No Relationships to Disclose
 
Xiaowen Sun
No Relationships to Disclose
 
Lei Feng
No Relationships to Disclose
 
Janelle Sanchez
No Relationships to Disclose
 
Melody Becnel
No Relationships to Disclose
 
Mahmoud Gaballa
Honoraria - Arcellx; Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - Arcellx; Bristol-Myers Squibb/Celgene
 
Hans Lee
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Allogene Therapeutics; Bristol Myers Squibb; GlaxoSmithKline; Janssen Research & Development; Menarini Silicon Biosystems; Pfizer; Regeneron; Sanofi; Takeda
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Regeneron; Takeda
 
Oren Pasvolsky
No Relationships to Disclose
 
Krina Patel
Leadership - Bristol-Myers Squibb/Celgene; Kite, a Gilead company; oricel
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Legend Biotech; Merck; Novartis; Pfizer; Regeneron; Takeda
Research Funding - Abbvie/Genentech; Celgene/Bristol-Myers Squibb; Indapta Therapeutics; Janssen; Nektar
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jing Ye
No Relationships to Disclose
 
Donna Weber
No Relationships to Disclose
 
Robert Orlowski
Stock and Other Ownership Interests - Asylia Therapeutics, Inc.
Consulting or Advisory Role - BioTheryX; Bristol-Myers Squibb; GlaxoSmithKline; IASO Biotherapeutics; Janssen; Lytica Therapeutics; Meridian Therapeutics; Monte Rosa Therapeutics; Regeneron; Sanofi; Takeda
Research Funding - Asylia Therapeutics, Inc. (Inst); CARsgen Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Exelixis (Inst); Heidelberg Pharma (Inst); Janssen Biotech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Asylia Therapeutics, Inc.
 
Sheeba Thomas
Consulting or Advisory Role - Cellectar
Research Funding - Abbvie; Bristol-Myers Squibb; Cellectar; Genentech; Sanofi/Aventis